FGFR2 and neoplasm: A recent study revealed that FGFR2 signaling drives NF-κB–dependent glycolysis in iCCA, and that treatment with pemigatinib, infigratinib, or futibatinib can effectively reprogram tumor metabolism, thereby conferring a novel targetable vulnerability in iCCA [133].